Retail crypto investors who are feeling the chill of the current market—BTC and ETH are still climbing but the fear‑greed index sits at 23, a level that signals widespread anxiety—might find a pause in the volatility of the crypto space by adding a more stable asset class. Healthcare stocks, especially those with diversified revenue streams, often offer a cushion against the swings that dominate digital assets.
Abbott Laboratories, with its broad portfolio ranging from diagnostics to medical devices, has a proven track record of steady cash flow and a diversified customer base. That breadth tends to smooth earnings in periods of economic uncertainty, making it a more conservative pick for those looking to balance risk in a portfolio that already includes crypto.
Glaukos, by contrast, focuses almost exclusively on ophthalmology devices. While the company could benefit from a surge in demand for eye‑care technology—particularly as the global population ages—its narrower product line and heavier reliance on regulatory approvals mean its performance can be more volatile. In a market that is already in extreme fear, such concentration can amplify risk.
The next few weeks will be telling. Both companies are slated to release earnings, and Glaukos is awaiting a critical FDA review that could either unlock a new revenue stream or stall its growth. Watching these catalysts will help investors gauge whether the stability of Abbott or the potential upside of Glaukos aligns better with their risk tolerance. As always, diversification across asset classes—including a mix of crypto, equities, and other securities—remains a prudent strategy for navigating the current market environment.